Ethinylestradiol, Chlormadinone acetate
Indications
Ethinylestradiol, Chlormadinone acetate is used for:
ETHINYL ESTRADIOL
For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive
CHLORMADINONE ACETATE
Cma has been used in the treatment of vaginal bleeding, oligomenorrhea, polymenorrhea, hypermenorrhea, secondary amenorrhea, and endometriosis. It has also been used clinically as a hormonal contraceptive, and in part due to its capacity to lower estrogen levels, but also for improved effectiveness in contraception, chlormadinone has frequently been combined with ethinyl estradiol for this purpose
For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive
CHLORMADINONE ACETATE
Cma has been used in the treatment of vaginal bleeding, oligomenorrhea, polymenorrhea, hypermenorrhea, secondary amenorrhea, and endometriosis. It has also been used clinically as a hormonal contraceptive, and in part due to its capacity to lower estrogen levels, but also for improved effectiveness in contraception, chlormadinone has frequently been combined with ethinyl estradiol for this purpose
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Ethinylestradiol, Chlormadinone acetate :
Mechanism of Action
ETHINYL ESTRADIOL
Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (shbg), thyroid-binding globulin (tbg), and other serum proteins and suppress follicle-stimulating hormone (fsh) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (gnrh)
CHLORMADINONE ACETATE
Cma acts predominantly as a potent progestogen, but also as an antiandrogen. Due to its potent actions as a progestogen, cma also has strong antigonadotropic properties, and thus additional antiandrogen as well as antiestrogen properties
Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (shbg), thyroid-binding globulin (tbg), and other serum proteins and suppress follicle-stimulating hormone (fsh) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (gnrh)
CHLORMADINONE ACETATE
Cma acts predominantly as a potent progestogen, but also as an antiandrogen. Due to its potent actions as a progestogen, cma also has strong antigonadotropic properties, and thus additional antiandrogen as well as antiestrogen properties